Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Ivonescimab (PD1/VEGF Bispecific) and Cadonilimab（PDL1/CTLA4 Bispecific）in Combination with Etoposide and Carboplatin As First-line Therapy in Patients with Extensive Stage Small Cell Lung Cancer

NCT06769971 is registered in ClinicalTrials.gov with Sichuan University as lead sponsor.

NCT NCT06769971
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06769971 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Ivonescimab (PD1/VEGF Bispecific) and Cadonilimab（PDL1/CTLA4 Bispecific）in Combination with Etoposide and Carboplatin As First-line Therapy in Patients with Extensive Stage Small Cell Lung Cancer
Lead sponsor
Sichuan University
Phase
Phase 2
Overall status
Recruiting
Start date
February 1, 2025
Completion date
December 31, 2027
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer